ClinicaliQ Trial Snapshot
- Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer — Active Not Recruiting • Non-phase study • Oncology • NCT02417662.
- Trial testing whether adding targeted radiation therapy to standard cancer drugs improves outcomes in patients with limited lung cancer spread.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The trial will assess the addition of stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy (SACT) in patients with oligometastatic non-small cell lung cancer. Patients will be randomised to receive either standard treatment alone (SACT) or standard treatment with conventional radiotherapy (RT) and SABR. Conditions: Non-small Cell Lung Cancer Interventions: Radical Radiotherapy (Conventional RT and SABR), Non-investigational SACT Lead Sponsor: University College, London Planned Enrollment: 140 participants